



RECEIVED

JUL 24 2002

TECH CENTER 1600/2900 MSK.P-042

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT (SUPPLEMENTAL)

Application No: 09/719494
Filing Date: 12/13/2000
First Named Inventor: Nikolich-
Zugich
Group Art Unit:
Examiner Name:
Attorney Docket No.: MSK.P-042

Page 1 of 2

Examiner's Initials	US Patent Document	Name of Patentee or applicant of cited document	Date of Publication of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	office	Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages where relevant passages appear	T ^o
MD	/	WO	95/29193	A2	The Government of the United States, represented by The Secretary, Department of Health and Human Services	02-11-1995	—	

M.D. 5/27/03



RECEIVED

JUL 24 2002

TECH CENTER 1600/2900

Examiner's
Initials

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

MD

Alexander B. H. Bakker, et al., Analogues of CTL Epitopes with Improved MHC Class-I Binding Capacity Elicit Anti-Melanoma CTL Recognizing the Wild-Type Epitope; Int. J. Cancer: 70, 302-309 (1997).

MD

Dyall, Ruben, et al; Heteroclitic Immunization Induces Tumor Immunity; J. Exp. Med., The Rockefeller University Press, Vol. 188, No. 9, Nov. 2, 1998, pps. 1553-1561.

MD

Kawakami, et al.; Human Melanoma Antigens Recognized by T Lymphocytes; Keio J. Med. 1996, 45 (2): 100-108.

MD

Lipford, et al., Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus turnour antigen, E6; 6199 Immunology

Pgs 298-303

84 Feb (2) 1995

MD

Overwijk, et al., gp100/pmel 17 Is a Murine Tumor Rejection Antigen; Induction of "Self"-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand; the Journal of Experimental Medicine; Vol. 188, No. 2, July 20, 1998, 277-286.

MD

Topalian, et al; Melanoma-specific CD4⁺ T Cells Recognize Nonmutated HLA-DR-restricted Tyrosinase Epitopes; J. Exp. Med., The Rockefeller University Press, 0022-1007/96/05/1965/07, Vol. 183, May 1996, 1965-1971.

MD

Tourdot, et al., Chimeric Peptides: A New Approach to Enhancing the Immunogenicity of Peptides with Low MHC Class I Affinity; The American Association of Immunologists, 1997. J. Immunology 159: 2391-2398.

MD

van der Burg, et al.; Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stability¹; The American 1996 Association of Immunologists; 0022-1767/96. J. Immunology 1996, 156: 3308-3314

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Examiner

MD

Date Considered

5/27/03

Examiner's Initials	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS
---------------------	---

MD

ANDERSON et al. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to Class I-restricted cell-mediated lysis. J. Exp. Med. August 1991, Vol. 174, pages 489-492, see entire document.

MD

ROGERS et al. Modulation of naive CD4 T cell activation with altered peptide ligands: the nature of the peptide and presentation in the context of costimulation are critical for a sustained response. J. Immunol. 1998, Vol. 160, pages 3698-3704, especially Abstract.

MD

RAMMENSEE et al. MHC ligands and peptide motifs: first listing. Immunogenetics. 1995, Vol. 41, pages 178-228, see entire document.

MD


SETTE et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. of Immunol. 1994, Vol. 153, pages 5586-5592, see entire document.

MD

WOLFEL et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 1994, Vol. 24, pages 759-764, see entire document.

MD

YEWDELL et al. MHC-encoded proteasome subunits LMP2 and LMP7 are not required for efficient antigen presentation. J. Immunol. 1994, Vol. 152, pages 1163-1170, see entire document.

M. D. 
5/27/03

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Examiner al R Date Considered 5/27/03